Aclaris Therapeutics to Participate in Inflammatory Skin Disease Conference

The clinical-stage biopharma company will present at the H.C. Wainwright virtual event.

Apr. 8, 2026 at 12:58pm

Got story updates? Submit your updates here. ›

Aclaris Therapeutics, Inc., a Pennsylvania-based biopharmaceutical company focused on developing novel treatments for immuno-inflammatory diseases, announced that its CEO Dr. Neal Walker and other senior leaders will participate in a fireside chat at the upcoming H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026.

Why it matters

As a clinical-stage biopharma company, Aclaris' participation in this high-profile industry conference signals its commitment to advancing new therapies for patients with inflammatory skin conditions who currently lack satisfactory treatment options.

The details

The fireside chat will take place at 12:00 PM EDT on April 14, 2026, and a live and archived webcast will be available on Aclaris' website for at least 30 days. Aclaris is developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases.

  • The conference will take place on April 14, 2026.
  • Aclaris' fireside chat is scheduled for 12:00 PM EDT on April 14, 2026.

The players

Aclaris Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases.

Dr. Neal Walker

The Chief Executive Officer of Aclaris Therapeutics.

Got photos? Submit your photos here. ›

The takeaway

Aclaris' participation in this influential industry conference underscores its commitment to advancing new treatments for patients with inflammatory skin conditions, an area of significant unmet medical need.